Abstract: An optical structure comprising at least one stack having a central filter (1) and two sandwiching optical elements (2,3) between which the central filter (1) is interposed, wherein the central filter (1) is in a matrix material. The matrix material being doped with at least one doping agent, the central filter (1) and the two optical elements (2,3) on either side thereof being assembled by bonding layers (4a, 4b) of a material based on the same matrix material as that of the central filter, the optical elements (2,3) on either side of the central filter (1) and the bonding layers (4a, 4b) each having a refractive index equal to that of the material of the central filter or only differing from this refractive index within a range of plus or minus 0.05, preferably within a range of plus or minus 0.02.

Abstract: The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.

Abstract: The invention concerns a method for calibrating a system for real-time measurement of the activity of a cognitive function of a test subject, the method comprising the successive steps of: acquiring electrical signals representative of a neural activity of a test subject; calculating values of markers of the cognitive function activity; generating a plurality of copies of calculated values of markers and adding noise to the generated copies; and, constructing a classifier by machine learning, based on the calculated marker values and noisy copies, the classifier being suitable for measuring the activity of the cognitive function of the test subject by calculating a probability that an electrical signal representative of the neural activity of the test subject results from a predetermined activity state of the cognitive function of the test subject.

Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as a drug, especially as an antibiotic. The present invention also relates to a pharmaceutical composition comprising said compound of formula (I) and at least one pharmaceutically acceptable excipient. The present invention further concerns a method of preparation of a compound of formula (I?).

Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.

Abstract: The invention concerns a system for controlling the temperature of a microfluidic chip comprising a Peltier module (10) having a cold face (10a) and a hot face (10b) and connected to a power generator (11), a thermal regulation device (12) having a thermal regulated face (12a) applied against one of the faces of the Peltier module, at least one temperature sensor (17) being applied on the other face of the Peltier module and being intended to be applied against one of the main faces of a microfluidic chip and control means (18) configured to control the power generator (11) of the Peltier module depending on a temperature of the face of the Peltier module provided with said at least one temperature sensor and at least one temperature setting information selected from a target temperature and a target temporal temperature profile to regulate a temperature of the face of the Peltier module to said temperature setting information.

Abstract: Method for non-invasively characterizing a heterogeneous medium using ultrasound, comprising a step of generating a series of incident ultrasonic waves, a step of recording an experimental reflection matrix Rui(t) defined between the input emission basis (i) and an output reception basis (u), a step of determining a response REP(r, ?r) of the medium between an input virtual transducer (TVin) calculated based on an input focusing of the experimental reflection matrix that creates an input focal spot around a first point (P1), and an output virtual transducer (TVout) calculated based on an output focusing of the experimental reflection matrix that creates an output focal spot around a second point (P2), said response being expressed as a function of a central point (PC) of spatial position (r) in the medium located midway between the first and second points (P1, P2).

Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.

Abstract: The disclosure provides for a composite material suitable for use as EMI shielding material, remarkable in that it comprises a component A being a polymer resin being at least one amorphous polymer resin and/or at least one semi-crystalline polymer resin selected from polyethylene resin and/or polypropylene resin; from 15.0 to 60.0 wt. % of component B being at least one metal-coated particle based on the total weight of the composite material; and from 0.5 to 5.0 wt. % of component C being one or more dispersants based on the total weight of the composite material; wherein one or more dispersants are selected from fatty acids, fatty acid derivatives, ethylene bis stearamide, functionalized waxes, maleic anhydride-grafted polymers and any mixture thereof; wherein the blend of components A, B and C shows a density ranging from 0.8 to 2.0 g/cc.

Abstract: The present invention relates to a polymer foam, said polymer foam comprising pores forming an open-cell polymer foam, said polymer foam comprising a supramolecular gel inside pores, and said polymer foam comprising at least one enzyme. The present invention relates to a supramolecular gel; its preparation and its applications, notably in chemical synthesis and kinetic resolution, in particular of organic compounds. The present invention also relates to flow chemistry.

Abstract: A hook fusion protein, which includes a hook domain and at least one cytoplasmic carboxyl endoplasmic reticulum (ER) retention signal and/or at least one cytoplasmic amino terminal endoplasmic reticulum (ER) retention signal; wherein the hook fusion protein is a soluble protein that localizes in the cytoplasm. Also, a nucleic acid system for intracellular targeting control including a nucleic acid encoding a target fusion protein including a hook fusion protein, and a nucleic acid encoding a target fusion protein including a hook-binding domain; wherein the target fusion protein is a membrane protein; and wherein the hook fusion protein localizes in the ER when bound to the target fusion protein. Additionally, a vector system, viral particle system, host cell and kit include these nucleic acids. Further, the vector system, viral particle system, host cell or kit for use as a medicament, in particular for immunotherapy.

Abstract: The present disclosure relates to a method for the preparation, from a mixture comprising (i) plant proteins, (ii) one or more plant tanning agents, (iii) one or more plasticizers, of a biobased material that may resemble animal leather.

Abstract: The invention is directed to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.

Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.

Abstract: A device for forcibly inserting a surgical implant into a receiving bone (4), by impaction, comprising an impactor (10) which exerts an impact force on the implant and is associated with at least one sensor (12). The sensor (12) measures the deformation of the impactor (10), and provides a measurement signal representing the temporal variation of the deformation during an impact. The sensor (12) is connected to a processing unit (30) configured to calculate, on the basis of the temporal variation of the deformation of the impactor (10) during the impact, an indicator representative of the level of contact between the implant and the receiving bone (4).

Abstract: A method for optimizing an existing generator system based on photovoltaic cells and provided with an existing photovoltaic panel or a group of existing photovoltaic panels, each panel having a first plurality of cells of a first type interconnected in series or in series/in parallel. The method includes: determining an operating voltage of the panel(s); producing additional panel module(s) having a second plurality of thin-film cells of a second type and having a different band gap width than the cells of the panel(s), the additional module(s) being configured to supply an operating voltage equal, within ±10%, to the voltage of the panel(s); positioning the additional module to overlap on or under the panel or one of the panel(s), the module being connected in parallel to the panel(s), or positioning several additional modules to overlap on or under several panels, the several modules being connected in parallel to panels.

Abstract: The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.

Abstract: A method for performing spacetime-constrained oblivious transfer between various laboratories of a first party A and various laboratories of a second party B. The method includes providing the spacetime-constrained oblivious transfer to satisfy various conditions. The method further includes encoding, by the laboratories of the first party A, various messages in a quantum state selected from various non-orthogonal quantum states. The method further includes transmitting, by the laboratories of the first party A, the quantum state to a first laboratory of the second party B. The method further includes applying, by the first laboratory of the second party B, a quantum measurement on the quantum state to obtain a classical measurement outcome. The method further includes transmitting, by the first laboratory of the second party B, the classical measurement outcome to the laboratories of the second party B.

Abstract: An active light-emitting layer composition including a thermally activated delayed fluorescence (TADF) molecule with TADF properties as a host material and a luminescent molecule with circularly polarized (CP) properties as a dopant. Also, a light-emitting device, such as an organic light-emitting diodes (OLED), including the active light-emitting layer made of this composition.

Abstract: The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.